Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

BACKGROUND: NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North A...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunkle, Lisa M., Kotloff, Karen L., Gay, Cynthia L., Áñez, Germán, Adelglass, Jeffrey M., Barrat Hernández, Alejandro Q., Harper, Wayne L., Duncanson, Daniel M., McArthur, Monica A., Florescu, Diana F., McClelland, R. Scott, Garcia-Fragoso, Veronica, Riesenberg, Robert A., Musante, David B., Fried, David L., Safirstein, Beth E., McKenzie, Mark, Jeanfreau, Robert J., Kingsley, Jeffrey K., Henderson, Jeffrey A., Lane, Dakotah C., Ruíz-Palacios, Guillermo M., Corey, Lawrence, Neuzil, Kathleen M., Coombs, Robert W., Greninger, Alex L., Hutter, Julia, Ake, Julie A., Smith, Katherine, Woo, Wayne, Cho, Iksung, Glenn, Gregory M., Dubovsky, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693692/
https://www.ncbi.nlm.nih.gov/pubmed/34910859
http://dx.doi.org/10.1056/NEJMoa2116185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693692/
https://www.ncbi.nlm.nih.gov/pubmed/34910859
http://dx.doi.org/10.1056/NEJMoa2116185

Ejemplares similares